INS and Hyperglycemia: The actions of the ELo in reducing hyperglycemia (Figure 3) and maintaining insulin levels close to those of normoglycemic animals and the glibenclamide group within 28 days suggest activation of β‐cells in the pancreas of hyperglycemic rats (Figure 4a).